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Abstract: Imiquimod (IMQ) is an immunostimulant drug topically used for 
the treatment of actinic keratosis and basal cell carcinoma. IMQ 
formulation and skin delivery is difficult because of its very low 
solubility in the most of pharmaceutical excipients and very poor skin 
penetration properties. The purpose of this study was to develop a 
microemulsion to optimise imiquimod skin delivery using D-α-tocopherol 
polyethylene glycol-1000 succinate (TPGS) as surfactant (so as to take 
advantage of its thickening properties) and isostearic acid as oil phase. 
This fatty acid was selected since it has demonstrated a good 
solubilizing power for imiquimod and it has also shown to contribute to 
its therapeutic activity. We have built pseudo-ternary diagrams using two 
different co-surfactants (Transcutol® and propylene glycol -PG) in a 1:1 
ratio with TPGS and then selected microemulsions in the clear and viscous 
regions of the diagrams. The systems were characterized in terms of 
rheology and X-ray scattering; additionally, the capability to promote 
IMQ skin uptake was evaluated ex-vivo on a porcine skin model. All the 
formulations selected in the gel-microemulsion regions behaved as 
viscoelastic solids; X-rays scattering experiments revealed in all cases 
the presence of an ordered lamellar structure, but with differences in 
terms of interlamellar distance and flexibility between Transcutol® and 
PG - containing systems. A higher flexibility and a greater hydrophobic 
volume, possibly interconnected at some point, was associated to the use 
of Transcutol® and had an impact on the microemulsion capacity to 
solubilize IMQ as well as on the capability to enhance drug uptake into 
the skin. The best performing gel-like microemulsion was composed of ≈ 
26% of water, ≈21% of isostearic acid, ≈26% of TPGS and ≈27% of 
Transcutol® and accumulated, after 6h of contact, 3.0 ± 1.1 µg/cm2 of 
IMQ. This value is higher than the one reported in the literature for the 
commercial cream (1.9 ± 0.8 µg/cm2), despite the 4-times lower 
concentration of the vehicle (13 mg/g for the microemulsion vs 50 mg/g 
for the commercial cream). 
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ABSTRACT 
Imiquimod (IMQ) is an immunostimulant drug topically used for the treatment of actinic keratosis 
and basal cell carcinoma. IMQ formulation and skin delivery is difficult because of its very low 
solubility in the most of pharmaceutical excipients and very poor skin penetration properties. The 
purpose of this study was to develop a microemulsion to optimise imiquimod skin delivery using 
D-α-tocopherol polyethylene glycol-1000 succinate (TPGS) as surfactant (so as to take advantage 
of its thickening properties) and isostearic acid as oil phase. This fatty acid was selected since it 
has demonstrated a good solubilizing power for imiquimod and it has also shown to contribute to 
its therapeutic activity. We have built pseudo-ternary diagrams using two different co-surfactants 
(Transcutol® and propylene glycol -PG) in a 1:1 ratio with TPGS and then selected microemulsions 
in the clear and viscous regions of the diagrams. The systems were characterized in terms of 
rheology and X-ray scattering; additionally, the capability to promote IMQ skin uptake was 
evaluated ex-vivo on a porcine skin model. All the formulations selected in the gel-microemulsion 
regions behaved as viscoelastic solids; X-rays scattering experiments revealed in all cases the 
presence of an ordered lamellar structure, but with differences in terms of interlamellar distance 
and flexibility between Transcutol® and PG – containing systems. A higher flexibility and a greater 
hydrophobic volume, possibly interconnected at some point, was associated to the use of 
Transcutol® and had an impact on the microemulsion capacity to solubilize IMQ as well as on the 
capability to enhance drug uptake into the skin. The best performing gel-like microemulsion was 
composed of ≈ 26% of water, ≈21% of isostearic acid, ≈26% of TPGS and ≈27% of Transcutol® and 
accumulated, after 6h of contact, 3.0 ± 1.1 µg/cm2 of IMQ. This value is higher than the one 
reported in the literature for the commercial cream (1.9 ± 0.8 µg/cm2), despite the 4-times lower 
concentration of the vehicle (13 mg/g for the microemulsion vs 50 mg/g for the commercial 
cream). 
*Abstract
  
We thank both the referee for their comments. We have answered to all of them and changed 
the text accordingly (in red in the manuscript). A point-by-point answer is here reported: 
 
 
Reviewer #1: the paper focuses on the design and development of microemulsion based system 
intended for skin delivery of imiquimod. the paper is interesting and few points should be 
clarified. 
 
general comments 
 
english should be revised. 
 
The language has been revised 
 
the reference products should be better 
described 
The composition of the reference product has 
been added to the text (page 19/20) 
“This result is particularly interesting, given the 10-fold 
different drug concentration (approx. 5 mg/g for the 
cited MEs vs 50 mg/g for Imunocare®), indicating a 
much better transport efficiency for the gel-like ME 
compared to the coarse emulsion (composition: 
isostearic acid, benzyl alcohol, cetyl alcohol, stearyl 
alcohol, white soft paraffin, polysorbate 60, sorbitan 
stearate, glycerol, methyl hydroxybenzoate, propyl 
hydroxybenzoate, xanthan gum and purified water).” 
 
the differences of the ex vivo experiments 
should be better stated also in the 
experimental part. 
The experimental conditions evaluated during 
the skin deposition experiments has been 
clarified in the method section (page 8).  
Formulations evaluated are reported in Table I, 
additionally, an IMQ saturated solution in isostearic acid 
was tested. All the donors were applied at infinite dose 
(200 mg/cm
2
, occluded) for 6 hours. In case of PG- 
containing MEs, two different drug loading were 
evaluated, with the drug present either in solution or in 
suspension. The detailed description of the preparation 
of the donor vehicles used is reported in section 2.9 
 
could hair influence the drug fate? 
 
Probably the follicular deposition of the drug 
can contribute to the results obtained (in 
particular, the deposition in the dermis can 
be affected), but –at the moment- this is just 
speculative, since this aspect has not been 
investigated here. Indeed, the role of a 
lamellar structure on drug deposition in the 
hair follicles it is an interesting topic, worth of 
further investigation.  
 
check the acknowledgements section. 
 
The section has been changed 
 
Reviewer #2: The author aimed to develop a microemulsion to optimise imiquimod skin delivery 
using D-<alpha>-tocopherol polyethylene glycol-1000 succinate (TPGS) as surfactant and 
*Response to Reviewers
isostearic acid as oil phase. The presence of isostearic acid can increase the stability of the 
formulation and potentially enhance the therapeutic activity. The presence of TPGS can 
contribute to enhance drug uptake, confer adequate rheological properties and deliver vitamin 
E to the skin tissue, possibly mitigating some local reactions. Although the experiment was 
designed well, there are still a few issues need to be solved before acceptance. 
 
1. The Pseudo-ternary phase diagram of the 
Smix/Oil/Water systems using acid as oil phase 
should be provided in figure 1 to demonstrate 
the important role of the co-surfactant in the 
formation of lamellar structures.  
 
Pseudo-ternary phase diagram obtained using 
PG and transcutol and oleic acid as oil phase 
were previoulsy published (Benigni 2018, Telò 
2016) and in our opinion it is not appropriate 
to reproduce it again. However, we agree on 
the fact that a comparison can be important 
to underline the role of the different 
components on the formation of the lamellar 
structure. For this reason, we have added 
data on the % of ME and ME gel regions for 
the 4 different combinations (ISO/PG, ISO/T, 
OLE/PG, OLE/T). A sentence is now present at 
page 11  
“The result highlights a relatively large gel-like region 
when the co-surfactant used was propylene glycol (14% 
of the diagram area), and a very small one when using 
Transcutol® (0.1% of the diagram area). A similar trend 
was previously obtained using oleic acid as oil phase, 
where the gel-like region decreased from 6% (in case of 
propylene glycol) to 2 % in case of transcutol (Benigni et 
al., 2018). This suggests an important role of the co-
surfactant structure and/or lipophilicity in the formation 
of lamellar structures.” 
 
2. The X-ray small angle scattering 2D image of 
ISO 20 PG should be provided in Fig 2 
 
The X-ray small angle scattering 2D image of 
ISO 20 PG has been inserted in Fig 2 
 
3. The intensity spectra of the SAXS and WAXS 
region in skin temperature should be provided 
in Fig 3 to demonstrate the correlation 
between water content and distances within 
the aggregated phase at both room and skin 
temperatures. 
 
The intensity spectra of the SAXS and WAXS 
region in skin temperature and the phase 
swelling behavior have been provided in Fig. 
3. The text has been modified accordingly. 
4. The abbreviations of isostearic acid in Table 
2 are unaligned with the abbreviations of 
isostearic acid in Table 1. 
The abbreviations have been corrected and 
are now homogeneous throughout the 
manuscript 
 
5. Imiquimod skin deposition from Oleic acid-
saturated solution should be performed. 
This experiment was performed in a previous 
paper. The value obtained and a comment 
have been now reported at pag 17. 
“This value is significantly higher than the one previously 
obtained from a saturated solution in oleic acid (IMQ 
solubility 73 mg/ml) that resulted 1.62 ± 0.40 µg/cm2 
(Telo et al., 2016b) This result confirms the enhancing 
property of ISO (Aungst, 1989), in particular toward IMQ 
permeation (Chollet et al., 1999). 
6. The amount of IMT separately found in 
epidermis and dermis should be presented in 
Fig 7. 
The data have been moved from the 
supplementary material to Figure 7 
 
7. The accumulation value obtained from the 
commercial cream Imunocare should be 
presented in Fig 8 to make a comparasion 
between the Transcutol®-containing 
microemulsions and the commercial cream 
Imunocare. 
The data has been added to Figure 8 
8. There is only one Transcutol®-containing 
microemulsion (ISO 25 T ), which is not enough 
to show a skin deposition higher than the one 
obtained with the commercial formulation. 
We only evaluated one formulation, because 
only this composition was able to generate a 
viscous system (see the very small 
overlapping area in Figure 1), characteristic 
that is essential to permit a dermal 
application. Indeed, as indicated in the 
conclusion (now red bold) this small design 
space can represent a problem, and it will be 
necessary to enlarge it. A possibility could be 
a change in the surfactant/cosurfactant ratio, 
but this will be the subject of further studies. 
The formulation ISO 25 T performed better 
than imunocare (now in Figure 8), despite the 
lower drug concentration. This is a good 
result, even if we agree with the reviewer 
that the enhancement obtained is not 
extraordinary. 
 
9.Some references about TPGS or TPGS based 
prodrug should be cited. 
 
References have been added. In particular, 
Collnot et al., 2007  
Zhang et al., 2012  
Muddineti et al., 2017 
Goddeeris et al, 2010 
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 2 
ABSTRACT 26 
Imiquimod (IMQ) is an immunostimulant drug topically used for the treatment of actinic keratosis 27 
and basal cell carcinoma. IMQ formulation and skin delivery is difficult because of its very low 28 
solubility in the most of pharmaceutical excipients and very poor skin penetration properties. The 29 
purpose of this study was to develop a microemulsion to optimise imiquimod skin delivery using 30 
D-α-tocopherol polyethylene glycol-1000 succinate (TPGS) as surfactant (so as to take advantage 31 
of its thickening properties) and isostearic acid as oil phase. This fatty acid was selected since it 32 
has demonstrated a good solubilizing power for imiquimod and it has also shown to contribute to 33 
its therapeutic activity. We have built pseudo-ternary diagrams using two different co-surfactants 34 
(Transcutol® and propylene glycol -PG) in a 1:1 ratio with TPGS and then selected microemulsions 35 
in the clear and viscous regions of the diagrams. The systems were characterized in terms of 36 
rheology and X-ray scattering; additionally, the capability to promote IMQ skin uptake was 37 
evaluated ex-vivo on a porcine skin model. All the formulations selected in the gel-microemulsion 38 
regions behaved as viscoelastic solids; X-rays scattering experiments revealed in all cases the 39 
presence of an ordered lamellar structure, but with differences in terms of interlamellar distance 40 
and flexibility between Transcutol® and PG – containing systems. A higher flexibility and a greater 41 
hydrophobic volume, possibly interconnected at some point, was associated to the use of 42 
Transcutol® and had an impact on the microemulsion capacity to solubilize IMQ as well as on the 43 
capability to enhance drug uptake into the skin. The best performing gel-like microemulsion was 44 
composed of ≈ 26% of water, ≈21% of isostearic acid, ≈26% of TPGS and ≈27% of Transcutol® and 45 
accumulated, after 6h of contact, 3.0 ± 1.1 µg/cm2 of IMQ. This value is higher than the one 46 
reported in the literature for the commercial cream (1.9 ± 0.8 µg/cm2), despite the 4-times lower 47 
concentration of the vehicle (13 mg/g for the microemulsion vs 50 mg/g for the commercial 48 
cream). 49 
  50 
 3 
1. INTRODUCTION 51 
D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS), is a water-soluble derivative of 52 
tocopherol, formed by the esterification of vitamin E succinate with PEG 1000. The presence of a 53 
lipophilic tail (tocopheryl succinate) and a hydrophilic head (PEG 1000) confers surfactant 54 
properties to this molecule, that has been widely used in pharmaceutical technology and drug 55 
delivery for its solubilisation and permeation enhancing properties (Grimaudo et al., 2018; Guo et 56 
al., 2013; Pham and Cho, 2017; Zhang et al., 2012). The capability to inhibit P-glycoprotein 57 
mediated efflux (Collnot et al., 2007) has widely promoted its use also in the formulation of 58 
antitumor drugs, to overcome anticancer drug resistance (Muddineti et al., 2017). 59 
Recently, this molecules has been used as a surfactant for the preparation of microemulsions for 60 
oral, nasal and dermal administration using different oil phases such as isopropylmiristate (IPM) 61 
(Suppasansatorn et al., 2007), oleoyl polyoxyl-6 glycerides (Labrafil® M 1944 CS) (Wan et al., 2017; 62 
Yao et al., 2009), omega-3 fatty acids  (Lee et al., 2016), propylene glycol monolaurate (Yao et al., 63 
2009), medium-chain triglyceride (Captex® 300) (Ke et al., 2005) and oleic acid (Benigni et al., 64 
2018; Suppasansatorn et al., 2007; Telò et al., 2017). Using oleic acid as oil phase, we have 65 
previously reported the possibility to obtain, for specific oil/smix/water ratio, gel-like 66 
microemulsions (Benigni et al., 2018). This possibility is particularly interesting in case of dermal 67 
application, since the viscosity extends the persistence of the formulation on the application area 68 
and, at the same time, enhances patient’s compliance (Marty et al., 2005). Even if extensively used 69 
for research purposes in ME formulations, oleic acid has some drawbacks, due to the low stability 70 
of the oxidable double bond. A possible alternative is represented by isostearic acid (ISO), a 71 
mixture of saturated fatty acids consisting mainly of methyl branched isomers of octadecanoic 72 
acid. Differently from stearic acid, isostearic acid is liquid at room temperature (melting 73 
point<10°C), displays solubilisation characteristics similar to oleic acid, but has higher resistance to 74 
oxidation. Its use in semisolid formulations is also supported by toxicological studies, showing lack 75 
of skin irritation or sensitization (“4 Final Report on the Safety Assessment of Isostearic Acid,” 76 
1983). FDA inactive ingredients database 77 
(https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm) indicates a maximum concentration 78 
of 25% w/w in topical formulations. Together with these properties, preliminary data suggest the 79 
capability of ISO to act as a penetration enhancer (Aungst, 1989) and, in particular, to increase 80 
imiquimod skin uptake (Chollet et al., 1999).  81 
 4 
Imiquimod (IMQ) is an immunostimulant drug topically used for the treatment of skin and mucosal 82 
infections, actinic keratosis and basal cell carcinoma. Its therapeutic effect is mediated by binding 83 
to Toll-like receptors 7 and 8, leading to the release of pro-inflammatory cytokines, chemokines 84 
and other mediators (Schon and Schon, 2007). IMQ has a very low solubility in many hydrophilic 85 
and lipophilic pharmaceutical excipients, but shows good solubility in fatty acids such as isostearic 86 
acid (Chollet et al., 1999). Additionally, it has been recently demonstrated that this fatty acid, 87 
present as oil phase in the commercial Aldara® cream, has a biological activity and executes 88 
additive or synergistic action with the drug (Walter et al., 2013).  89 
The aim of this work was the preparation and the characterization of viscous microemulsions, 90 
containing TPGS as surfactant and isostearic acid as oil phase, for imiquimod skin delivery. The 91 
presence of isostearic acid can increase the stability of the formulation and potentially enhance 92 
the therapeutic activity. The presence of TPGS can enhance drug uptake (Pham and Cho, 2017; 93 
Yang et al., 2018), confer adequate rheological properties and deliver vitamin E to the skin tissue, 94 
possibly mitigating some local reactions, as reported by Wan et al. (Wan et al., 2017). Indeed, the 95 
release of vitamin E from TPGS, in the presence of esterase, has been demonstrated in vitro 96 
(Grimaudo et al., 2018), and the presence of esterase activity in the stratum corneum is well 97 
documented (Beisson et al., 2001; Lau et al., 2012).  98 
In the present work we have 1) evaluated the feasibility of isostearic acid-based gel-like 99 
microemulsions using TPGS as surfactant, by building pseudo-ternary diagrams using two different 100 
co-surfactants (Transcutol® and propylene glycol); 2) characterized the prepared systems in terms 101 
of rheology and mesostructure by X-ray scattering; 3) evaluated the capability of the gel-like 102 
systems to promote imiquimod skin uptake using an in-vitro skin model.  103 
 104 
2. MATERIALS AND METHODS 105 
2.1. Materials  106 
IMQ (MW: 240.3 g/mol; pKa: 7.3) was purchased from Hangzhou Dayangchem, (Zhejiang, China). 107 
Oleic acid was purchased from Alfa Aesar (Karlsruhe, Germany) and isostearic acid was a kind gift 108 
from Biochim (Milan, Italy). D-α-Tocopheryl polyethylene glycol 1000 succinate (Kolliphor® TPGS, 109 
MW: 1513 g/mol) was a kind gift from BASF (Ludwigshafen, Germany) and from ISOCHEM 110 
(Gennevilliers, France). Transcutol® was a gift from Gattefossè (Lyon, France). 1,2-propanediol 111 
(MW: 76 g/mol) was purchased from A.C.E.F. S.p.A. (Fiorenzuola d’Arda, Italy) while 70% 112 
perchloric acid solution, trimethylamine (TEA) and albumin from bovine serum from Sigma Aldrich 113 
 5 
(St. Louis, MO, USA). For HPLC analysis, pure water (Purelab® Pulse, Elga Veolia, UK) and HPLC 114 
grade acetonitrile and methanol were used.  115 
 116 
2.2. Imiquimod quantification method  117 
Imiquimod was quantified by HPLC (Flexar, Perkin Elmer, Waltham, MA, USA), with a reverse-118 
phase C18 column (Kinetex C18 2.6 µm, 100 Å, 75 x 4.6 mm, Phenomenex, Torrance, CA, USA), a 119 
C18 guard column (SecurityGuard Widepore C18, Phenomenex, Torrance, CA, USA) and either UV 120 
or fluorescence detection. The mobile phase, pumped at 0.5 ml/min, was a mixture 121 
CH3OH/CH3CN/H2O/TEA (180/270/530/20). In these conditions, imiquimod retention time was 122 
about 4 min. In the case of samples from tissue extraction and permeation experiments, 123 
fluorescence detection (λexc 260 nm, λem 340 nm) was used (injection volume: 1 μl), while samples 124 
used for imiquimod solubility assessment were analysed by UV absorbance (λ 242 nm; injection 125 
volume: 10 μl). The HPLC methods were previously validated for sensitivity, precision and accuracy 126 
in the concentration intervals 0.03-3 µg/ml for fluorescence detection and 1- 50 µg/ml for UV 127 
detection (Telo et al., 2016a). 128 
 129 
2.3. Pseudo-ternary phase diagram construction 130 
Pseudo-ternary phase diagrams were built to identify the microemulsion, gel-microemulsion and 131 
gel regions in multiphasic systems. Either oleic acid or isostearic acids were used as oil phase, and 132 
a 1/1 (w/v; g/ml) mixture of TPGS and co-surfactant (either Transcutol® or 1,2-propanediol) was 133 
used as surfactant system (Smix). The diagrams were built using the aqueous tritration method, 134 
consisting in the addition of increasing amounts of water (between 5 and 95%) to fixed ratios 135 
oil/Smix, namely 0.5/9.5, 1/9, 1.25/8.75, 2/8, 3/7, 4/6, 5/5, 6/4, 7/3, 8/2, 9/1. After each addition, 136 
the mixture was vortexed and left 2 minutes to rest, then by visual observation the viscosity and 137 
clearness of the system were evaluated. In case of highly viscous systems, the mixture was heated 138 
in a water bath at 50°C before each water addition to reduce the viscosity, favour the mixing and 139 
achieve homogeneity. The evaluation of the system was performed after cooling at room 140 
temperature. The formulation belongs to the microemulsion region if it is clear and exhibits low 141 
viscosity, while to the microemulsion-gel region if clear and viscous. The diagrams were built using 142 
OriginPro® 2016 (Originlab, Northampton, MA, USA). 143 
 144 
2.4. Imiquimod solubility 145 
 6 
IMQ solubility was determined in isostearic acid and in the oil/Smix mixtures oleic 146 
acid/(TPGS+Transcutol®); isostearic acid/(TPGS+Transcutol®) and isostearic acid/(TPGS+propylene 147 
glycole). The oil/Smix ratio was always 3/7, while the surfactant:co-surfactant ratio was always 1:1 148 
(p:v).  149 
Briefly, an excess amount of IMQ was added to the different vehicles, and after 24 hour mixing, 150 
the suspension was centrifuged (13000 rpm, 10 minutes). The supernatant was filtered 151 
(regenerated cellulose, 0.45µm), diluted and analysed by HPLC-UV for the accurate determination 152 
of the solubility. 153 
 154 
2.5. Rheological behavior 155 
Rheological data were collected in oscillation mode, using a cone and plate geometry, with an Ares 156 
Rheometer (TA Instruments, New Castle, DE, USA) controlled by Orchestrator software (TA 157 
instruments, New Castle, DE, USA). Cone (diameter: 50 mm; angle: 0.04 rad) was made of plastic. 158 
Sample’s linear viscoelastic region (LVE) was determined by strain sweep (10−2-10+2 strain %) at 159 
23 °C; dynamic frequency sweep test was then carried out, at the same temperature, at 0.1 % 160 
strain for ISO 11 PG and at 0.06% strain for all other samples. 161 
 162 
2.6. Polarized optical microscopy 163 
To assess gel-microemulsions optical properties, MEs were spread onto a glass slides and 164 
immediately covered with a cover slip to prevent water loss. Samples were analysed at 20X 165 
magnification using a polarized optical microscope (Nikon, Shinjuku, Japan) and images were 166 
taken with a 13 megapixels camera (Samsung Galaxy S4, Seoul, South Korea).  167 
 168 
2.7. X-ray scattering experiments 169 
Small-angle and wide-angle X-ray scattering experiments were carried out to study the internal 170 
structure of formulations on length-scales from tens of nanometers down to the tenths of 171 
nanometers (Sandri et al., 2017; Telò et al., 2017). Measurements were performed at ESRF 172 
Synchrotron (Grenoble, France) on the ID02 high-brilliance beamline in the region of momentum 173 
transfer 0.0116 < q < 40 nm-1, where q = (4π/λ) sin(θ), 2θ is the scattering angle and λ = 0.1 nm is 174 
the incident X-ray wavelength. Samples were measured at 23°C and 33°C, i.e. at normal storage 175 
temperature and close to the temperature of the skin. Very short acquisition time was chosen (0.1 176 
s) to avoid any possible radiation damage. 2D intensity patterns were analysed to evidence the 177 
 7 
internal organization of different formulations, the presence of intensity rings or arcs indicated 178 
ordered internal structures (Cantù et al., 2017). 2D patterns were angularly regrouped to obtain 179 
the intensity spectra I(q) and analysed to calculate the structural parameters of each formulation.  180 
 181 
  182 
All the formulations analysed were blank (without drug) and characterised by a 3/7 oil/Smix ratio. 183 
In particular ISO 25 T, its analogue with oleic acid (OLE 25 T), and seven ME containing PG as co-184 
surfactant along the water dilution line (from ISO 11 PG and ISO 25 PG, see Table I and Figure 1b) 185 
were evaluated.  186 
 187 
2.8. Imiquimod-loaded gel microemulsion  188 
Table I. Composition (% w/w)
a 
of the imiquimod-loaded gel-like ME prepared. For all the formulations, the surfactant 189 
was TPGS and the oil/Smix ratio was 3/7.  190 
CODE
b
 Oil Phase % Co-surfactant % Surfactant 
(TPGS) % 
Water % IMQ conc (mg/g) 
OLE 25 T Oleic acid  20.5 Transcutol® 26.7 26.9 25.9 11.8 
ISO 25 T Isostearic acid  20.5 Transcutol® 26.7 26.9 25.9 13 
ISO 11 PG Isostearic acid  24.1 propylene glycol 32.9 31.7 11.3 21.2
c
 5.3 
ISO 16 PG Isostearic acid  22.6 propylene glycol 31.1 30.0 16.3 20.0
c
 5.0 
ISO 20 PG Isostearic acid  21.7 propylene glycol 29.5 28.5 20.3 19.1
c
 4.8 
ISO 25 PG Isostearic acid  20.4 propylene glycol 27.5 26.5 25.6 17.8
c
 4.5 
a 
the following densities
 
were used for the calculation: isostearic acid:0.89 g/ml; propylene glycol:1.04 g/ml; 191 
Transcutol®:0.99 g/ml 192 
b
The code is given by the oil phase used - Oleic(OLE) or Isostearic (ISO) acid, followed by the water percentage and by 193 
the co-surfactant used (T:Transcutol®, PG:propylene glycol )
 194 
c
The drug is partially suspended 195 
 196 
In order to obtain IMQ loaded gel-microemulsions, the oil/Smix mixtures (ratio: 3/7) were 197 
saturated with IMQ (see section 2.4). Then, known volumes of water were added to obtain the 198 
final water % (Table I). The microemulsions were heated at 50°C and vortexed to achieve 199 
homogeneity. No precipitation occurred upon water addition in case of OLE 25 T and ISO 25 T. On 200 
the contrary, IMQ precipitated from the gelled microemulsions prepared with propylene glycol as 201 
co-surfactant, originating white suspensions. The same vehicles were then prepared starting from 202 
a 6 mg/ml IMQ solution in oil/Smix mixture. 203 
The composition of the formulations prepared is shown in Table I together with the concentration 204 
of imiquimod. 205 
 206 
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2.9. Stratum corneum (SC) uptake experiments 207 
Epidermis was isolated by soaking full thickness pig ear skin in distilled water at 60°C for 120 s.  208 
SC sheets were prepared by soaking isolated epidermis samples in 1% (w/v) trypsine in pH 7.4 PBS, 209 
at 4°C for 15 hours. Epidermis was then removed with a cotton swab and SC sheets obtained were 210 
carefully rinsed with distilled water, placed on siliconized paper and dried in oven at 37°C for 1 h. 211 
The samples were then kept in a dessiccator on CaCl2 until use (Nicoli et al., 2008). For uptake 212 
experiments, SC sheets (≈1.6 mg/cm2, area of approximately 2.5 cm2) were weighted (Mettler 213 
Toledo, sensitivity 0.001 mg) and then individually soaked in 2 ml of isostearic acid solutions 214 
containing imiquimod at 0.5, 1.5 or 3 mg/ml concentration. The vials were kept in a temperature-215 
controlled oven at 32±1°C; after 6 h SC sheets were removed from the vehicle, carefully dried 216 
using filter paper and re-weighted. Isostearic acid uptake was calculated as: 217 
%Weight increment=((Wf−Wi)/Wi)×100   Equation 1 218 
where Wf is final weight and Wi is initial weight of SC sheet.  219 
IMQ was then extracted from the SC sheets using 1 ml of oleic acid:methanol mixture (1:3) 220 
overnight at room temperature (Telo et al., 2016a). 221 
 222 
2.10. Accumulation and permeation experiments 223 
For permeation experiments, porcine skin excised from the outer part of pig ears was used. The 224 
skin was separated from the underlying cartilage with a scalpel, frozen at -20°C and used within 3 225 
months. The skin, once thawed, was mounted on glass Franz-type diffusion cells (DISA, Milano, 226 
Italy; 0.6 cm2 surface area) with the stratum corneum facing the donor compartment. The 227 
receptor compartment contained 1% w/v albumin solution in PBS pH 7.4 (IMQ solubility: 143 ± 3 228 
µg/ml). Formulations evaluated are reported in Table I, additionally, an IMQ saturated solution 229 
in isostearic acid was tested. All the donors were applied at infinite dose (200 mg/cm2, 230 
occluded) for 6 hours. In case of PG- containing MEs, two different drug loading were evaluated, 231 
with the drug present either in solution or in suspension. The detailed description of the 232 
preparation of the donor vehicles used is reported in section 2.9.  233 
At the end of the experiments, the receptor solution was sampled and the donor formulation was 234 
carefully removed. The skin surface was then rinsed with distilled water, blotted dry and tape-235 
stripped twice (Scotch Booktape #845, 3M Co., St Paul, MN, USA) to remove possible traces of the 236 
formulation. Skin samples were then heated (hairdryer for 60 seconds) and separated into 237 
epidermis and dermis with the help of a spatula. IMQ extraction from the tissues was performed 238 
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overnight at room temperature using either 1 ml of oleic acid:methanol (1:3) (epidermis) or 1 ml 239 
of PEG 400:methanol:HCl 1M (1:2:2) (dermis). To evaluate IMQ permeation, 1 ml of the receptor 240 
solution was sampled, added of 50 µl of 70% v/v perchloric acid to precipitate albumin and 241 
centrifuged (12000 rpm, 15 minutes). Samples were analysed by HPLC-fluorescence. The 242 
extraction procedure was previously validated (Telo et al., 2016a).  243 
  244 
 10 
3. RESULTS AND DISCUSSION 245 
TPGS is a surfactant showing peculiar properties. Thanks to its ability to form ordered lamellar 246 
structures , it has been used to prepare gel-like systems without the need of any thickening agent, 247 
using oleic acid as oil phase (Benigni et al., 2018).  248 
 249 
3.1. Pseudo-ternary diagram 250 
The first step was the evaluation of the possibility to obtain gel-like microemulsions using 251 
isostearic acid as oil phase, to take advantage of the stability of this fatty acid and of its 252 
therapeutic contribution (Walter et al., 2013). So, a phase diagram was built using two different 253 
co-surfactants, namely Transcutol® and propylene glycol, in a 1:1 ratio with TPGS and isostearic 254 
acid (ISO) as oil phase. 255 
 256 
 257 
 258 
Figure 1: Pseudo-ternary phase diagram of the Smix/Oil/Water systems. The oil phase is isostearic acid, Smix is a 259 
mixture of TPGS/co-surfactant 1/1 (w/v). Co-surfactants used are propylene glycol and Transcutol®. The blue region 260 
indicates low-viscosity transparent formulations, the white region indicates viscous formulations; the overlapping 261 
domains represent clear and highly viscous formulations. In the uncolored region, low viscosity coarse turbid 262 
emulsions or phase-separated systems were found. The red arrows in the propylene glycol diagram show the water 263 
dilution line investigated (water from 11 to 25%). A representative polarized-light microscope image illustrating the 264 
presence of Malta crosses is also shown. 265 
 266 
ISO	25	T
Co-surfactant:	
Transcutol®
Co-surfactant:	
Propylene	glycol	(PG)
% Oil % Oil
 11 
The result highlights a relatively large gel-like region when the co-surfactant used was propylene 267 
glycol (14% of the diagram area), and a very small one when using Transcutol® (0.1% of the 268 
diagram area). A similar trend was previously obtained using oleic acid as oil phase, where the 269 
gel-like region decreased from 6% (in case of propylene glycol) to 2 % in case of transcutol 270 
(Benigni et al., 2018). This suggests an important role of the co-surfactant structure and/or 271 
lipophilicity in the formation of lamellar structures. 272 
In the clear and viscous regions, some MEs were selected and characterized, since vehicles 273 
belonging to this region could –  at least in principle - take advantage of the enhancing properties 274 
of the ME and the rheological properties of a gel, necessary for a feasible skin application. All the 275 
selected ME had an oil/Smix ratio of 3/7, so as to contain a relevant amount of isostearic acid, 276 
necessary for boosting the therapeutic efficacy of IMQ (Walter et al., 2013). Their composition is 277 
detailed in Table I. In the case of Transcutol®-based ME one formulation was selected, while in 278 
case of propylene glycol, different MEs along the 3/7 oil/Smix dilution line (see Figure 1) were 279 
chosen, with a water concentration included between 11 and 25% w/w. To evaluate the influence 280 
of fatty acid, a ME containing oleic acid as oil phase was also evaluated (OLE 25 T). Its composition 281 
(Table I) was the same as ISO 25 T, except for the different fatty acid. The pseudo-ternary diagram 282 
related to oleic acid, TPGS and Transcutol® was previously published (Telò et al., 2017), but this 283 
ME was never evaluated before. 284 
 285 
3.2. Characterization of blank microemulsions 286 
 287 
3.2.1. Polarized-light microscopy 288 
The thickening of the microemulsion, obtained for specific oil/Smix/water proportions, is linked to 289 
the capability of TPGS to form ordered structures{Goddeeris:2010in}. A preliminary analysis using 290 
polarized light microscope highlighted the presence of Malta crosses for all the gel-like 291 
microemulsions. The different oil phase (oleic acid vs isostearic acid) or co-surfactant (Transcutol® 292 
vs PG) did not apparently impact on the structure of the system. Figure 1 report a representative 293 
image, others are presented in Supplementary material (Figure S1).  294 
 295 
3.2.2. X-ray scattering 296 
 12 
X-ray scattering experiments were first performed to study the structure of the MEs containing PG 297 
as co-surfactant in the range of water content 11-25 %, with an oil/Smix ratio 3/7 (see Figure 1) 298 
both at room and skin temperatures (23 and 33 °C).  299 
In the small-angle region (SAXS) the characteristic 2D patterns, as reported in Figure 2 for PG-300 
containing MEs, showed several concentric rings, indicating a well-defined internal structure on 301 
the supramolecular length-scale. Interestingly the intensity of each ring was not uniform, rather 302 
equatorial arcs were visible for all samples. This peculiar feature was the sign that the 303 
formulations consisted of partially aligned structures with characteristic repetitions along the 304 
vertical axis. As the samples have been inserted into capillaries (diameter: 2 mm), measured in a 305 
horizontal position, these results indicate that formulations, while flowing, assumed a regular 306 
internal spacing in the direction perpendicular to insertion. This alignment was more evident at 307 
low water content.  308 
 309 
 310 
 311 
Figure 2. X-ray small angle scattering 2D images relative to ME containing 3/7 oil/Smix ratio, PG as co-surfactant 312 
and different water %. From left to right ISO 11 PG, ISO 18 PG, ISO 20 PG, ISO 25 PG, T = 23 °C.  313 
  314 
 315 
After angular regrouping, each of the scattered intensity profiles presented three peaks with 316 
decreasing height (see Figure 3a, T = 23 °C and 3d, T = 33°C). The q position of the subsequent 317 
peaks was a multiple of the first one, qn = nq1, indicating lamellar ordered structures. The inter-318 
lamellar distance was about 7.6 nm at both temperatures for the ISO 11 PG, with the lowest 319 
water content. Increasing the water content, we observed a left shift of the peaks corresponding 320 
to longer characteristic distances within the aggregated phase (d ÷ 1/q) from 7.6 nm to 9.3 nm. In 321 
parallel the second and third peaks became higher indicating that the lamellae progressively 322 
organized in more ordered structures. 323 
 324 
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 325 
   
Figure 3. X-ray scattering results relative to ME containing 3/7 oil/Smix ratio, PG as co-surfactant and different 326 
water % as indicated in figure at T = 23°C (a, b,c) and at T = 33°C (d,e,f). Panel a,d: SAXS intensity profiles versus q as 327 
a function of water content. Panel b,e: Swelling behaviour of MEs. Apolar volume fraction φapol as a function of the 328 
characteristic distance d calculated from the first peak position in SAXS intensity profiles  d = 2π/qpeak. The line is 329 
the best fit obtained from equation φapol   d
-s
 with s = 1. Panel c,f:  Plots of WAXS intensity profiles versus q as a 330 
function of water content.  331 
 332 
The swelling behavior can provide further information on the structural properties of the 333 
formulation. In fact, given the general swelling dependence φapol  d
-s, in which φapol is the apolar 334 
volume fraction, the value of the exponent s is connected to the phase of the system, for example, 335 
s=1 for the lamellar phase (monodimensional swelling), s=2 for the hexagonal phase 336 
(bidimensional swelling), s=3 for the micellar phase (tridimensional swelling). Figures 3b and 3e 337 
report the apolar volume fraction φapol (calculated as [(φisostearic + φvitE)]) as a function of the 338 
characteristic distance d for the formulations in the range 11-25% of water content. The distance d 339 
was calculated from the position of the first or subsequent peaks d= 2π/(qpeak/n), where n is the 340 
order of the peak, n=1 for the first peak. The linear fits of the experimental points gave a slope of 341 
s=1, characteristic for the swelling behavior of lamellar structures, at both temperatures. 342 
Knowing the volume fraction φapol and the interlamellar distance, we calculated that the thickness 343 
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of the apolar layer was about 2.8 nm, enclosed between layers of propylene glycol, polyethylene 344 
glycol groups of TPGS and water.  345 
Parallel Wide Angle X-ray Scattering (WAXS) measurements were performed on the same samples 346 
to obtain structural information on the very local length-scale, corresponding to the distance 347 
between lipid chains in the apolar region. WAXS spectra are reported in Figure 3c (T = 23 °C) and 348 
3f (T = 33°C). 349 
The presence of a structure peak at q = 13.9 nm-1 (T =23 °C) and q = 13.8 nm-1 (T =33 °C) indicated 350 
a local order in the lipid region with a mean characteristic distance of dlocal = 0.452 nm (T =23 °C) 351 
and dlocal = 0.455 nm (T =33 °C). This local order wasn’t affected by the addition of increasing 352 
amount of water in the investigated formulations.  353 
To elucidate the role of the different excipients on the final structure of MEs, we compared the 354 
spectra obtained from ME with the same oil/Smix ratio (3/7), the same water content (25%) but a 355 
different co-surfactant or oil phase. Figure 4a reports the intensity spectra in the SAXS and WAXS 356 
regions of two ME prepared with isostearic acid and either Transcutol® (orange) or PG (violet) as 357 
co-surfactant. On the mesoscale, the results showed a definitely different interlamellar distance: d 358 
= 9.2 nm in presence of PG and d = 7.6 nm in presence of Transcutol®. This finding was not 359 
unexpected, being the propylene glycol more hydrophilic and hydrated, while Transcutol® could 360 
better insert into the oil region. 361 
 362 
 363 
 364 
  
Figure 4.  X-ray scattering results relative to ME containing 25% water and 3/7 oil/Smix ratio with different co-365 
surfactants and oils (T = 23°C). Panel a: SAXS ( left) and WAXS (right) intensity profiles versus q of ME 25 with 366 
isostearic acid and PG co-surfactant (violet) or Transcutol® co-surfactant (orange). Panel b: SAXS (left) and WAXS 367 
(right) intensity profiles versus q of ME 25 with Transcutol® co-surfactant and isostearic acid (orange) or oleic acid 368 
(green).  369 
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 370 
In the WAXS region we observed in both samples a first peak centered at the same q = 14 nm-1 ( d 371 
= 0.45 nm), see Figure 4a, but in presence of Transcutol® the intensity spectrum showed also a 372 
second peak or shoulder, centered around 16.5 nm-1, corresponding to a shorter characteristic 373 
distance d2 = 0.38 nm. This result indicated that lipid chains underwent a "phase separation" 374 
within the single bilayer between regions with closer and looser packing.  375 
Finally, we compared formulations containing Transcutol® as co-surfactant and different oil phases 376 
(isostearic or oleic acid) at a given oil/Smix ratio and water content (ISO 25 T and OLE 25 T in Table 377 
I). The substitution did not affect the main features of the MEs structures. Similar results on both 378 
the mesoscale and the local length-scale were found (Figure 4b), with the characteristic phase 379 
separation within the single lamella observed due to the presence of Transcutol®. Moreover, we 380 
observed that in presence of Transcutol® both the formulations, with isostearic and oleic acid, did 381 
not align internally when they are pushed into capillaries, as the one containing PG (Figure 2), as 382 
visible in Fig. S2 (Supplementary material) that shows uniform intensity rings; this means that the 383 
systems were able to keep or recover their structure when submitted to confinement and flow. 384 
These results, i.e. the presence of uniform intensity rings, the "phase separation" within the single 385 
bilayer between regions with closer and looser packing (WAXS), the lower interlamellar distance 386 
(7.6 nm) due to Transcutol® surfactant properties, and the absence of the third peak in the SAXS 387 
intensity profile (Figure 4a) suggest a more flexible structure in the presence of Transcutol®, that 388 
could be associated to the presence of less-organized and connected lamellar structures. On the 389 
other hand, the presence of a single peak in WAXS region, the presence of equatorial arcs (Figure 390 
2), the higher interlamellar distance (9.2 nm) and the presence of an evident third peak in the 391 
SAXS intensity profile (Figure 4a) suggest, in case of PG, a more rigid and organized structure, 392 
characterized by non-interconnected lamellae and a hydrophilic region where the water is 393 
engaged by PG and PEG chains. Indeed, as discussed in the following section, PG-containing and 394 
Transcutol®-containing systems behave very differently with respect to the capability to maintain 395 
imiquimod in solution upon water dilution.  396 
 397 
3.2.3. Rheological behaviour  398 
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 399 
Figure 5. Panel a represents the loss factor (tan delta; G’’ and G’ ratio): when G’’ > G’, the loss factor is greater than 1 400 
and material is a viscoelastic liquid; when G” = G’, the loss factor is equal to 1 (dashed line), and material show both 401 
viscous and elastic behaviour; finally, when G’’ < G’, the loss factor is lower than 1 (the present case), and sample 402 
behaves as viscoelastic solid. Panel b reports the complex viscosity (eta*, Pa.s) against angular frequency (rad/s). The 403 
decline of viscosity as consequence of increase of the angular frequency may be translate in term of spreadability, a 404 
desirable characteristic for a topical dosage form. Data were collected in oscillatory mode, at 23°C and 0.1% strain for 405 
ISO 11 PG and at 0.06% strain for all other samples, using a cone and plate geometry. 406 
 407 
All microemulsions behave as viscoelastic solid, with a strong gel structure. In fact, G’ (i.e. the 408 
storage modulus) is higher than G” (i.e. the loss modulus), as gathered from Figure 5a, where the 409 
loss factor (tan delta, i.e. G’’ and G’ ratio) is always lower than 1 (see also Supplementary material, 410 
where Figure S3, reports the rheological profiles of the single MEs). Differences in oil phase 411 
(isostearic acid vs oleic acid), slightly affected the rheological profile, as shown in Figure 5b. In fact, 412 
the complex viscosity (eta*; Pa.s) in presence of oleic acid (OLE 25 T) is lower than that of ME 413 
containing isostearic acid (ISO 25 T). This result is not affected by co-surfactant, since when 414 
Transcutol® is replaced by PG (ISO 25 T vs ISO 25 PG), no difference in complex viscosity is 415 
observable. Finally, ISO 11 PG, the ME containing the smaller percentage of water, exhibits lower 416 
complex viscosity values, if compared to ISO 16-20-25 PG and, indeed, it is located at the edge of 417 
the gel like region in the pseudo-ternary diagram.  418 
Rheological properties correlated with structural ones. At low water content (ISO 11 PG), where 419 
we observed the lowest complex viscosity, ME became pretty aligned internally while flowing into 420 
capillaries, as reported in Figure 2. This alignment was less evident, but still detectable at higher 421 
water content and could be connected to the decrease of the shear viscosity on increasing the 422 
shear rate, as inferable from the complex viscosity behaviour against angular frequency reported 423 
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in Figure 5b. These results can give interesting insights in view of the development of formulations 424 
for topical applications with the desired spreadability.  425 
 426 
3.3. IMQ solubility and loading into the MEs 427 
Imiquimod solubility was evaluated in isostearic acid and in the 3/7 oil/Smix mixtures. The results 428 
(Table II) are compared with the solubility obtained in a previous paper (Telo et al., 2016a) with 429 
oleic acid, pure Transcutol® and pure propylene glycol. The data show the 2 fold higher solubility 430 
of IMQ in isostearic acid with respect to oleic acid. The addition of the mixture TPGS:Transcutol® 431 
(1:1) to obtain an oil/Smix ratio of 3/7, drastically reduced IMQ solubility to approx. 15 mg/ml, 432 
regardless the fatty acid contained. When using propylene glycol instead of Transcutol®, drug 433 
solubility in the oil/Smix increased, despite the IMQ solubility in the pure co-solvent was double 434 
for Transcutol® with respect to PG.  435 
 436 
Table II. Imiquimod solubility in the oil phases, co-surfactants and oil/Smix 3/7 mixtures 437 
Vehicle Solubility (mg/ml) 
ISO 154 ± 0.85 
OLE 73.86 ±14.2* 
Propylene glycol 0.60 ±0.03* 
Transcutol® 1.11 ±0.07* 
OLE/TPGS/Transcutol® (3/4.5/4.5) 13.40 ± 1.28 
ISO/TPGS/Transcutol® (3/4.5/4.5) 16.21 ± 0.13 
ISO/TPGS/propylene glycol (3/4.5/4.5) 23.93 ± 2.83 
* From ref.(Telo et al., 2016a) 438 
 439 
In order to prepare the gel-like systems, water was added to the saturated oil/Smix (3/7 ratio) 440 
solution. Due to the very low aqueous solubility, the addition of water to the isostearic 441 
acid/TPGS/PG saturated mixture caused drug precipitation and the formation of a white, gel-like 442 
suspension. To avoid this phenomenon, imiquimod was also dissolved in the isostearic acid 443 
/TPGS/PG mixture at 6 mg/ml concentration. Upon water addition, ISO 11 PG, ISO 16 PG and ISO 444 
20 PG were transparent, while a slight opalescence was present in case of ISO 25 PG.  445 
Contrarily to the behaviour seen with PG, the addition of water up to 25% to the vehicles 446 
containing Transcutol® (OLE 25 T and ISO 25 T) did not cause any drug precipitation, suggesting 447 
that the more flexible mesostructure, characterized by a greater hydrophobic volume, possibly 448 
interconnected at some point, allows a more efficient loading of the drug, at the same time 449 
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preserving it from the unfavorable contact with the aqueous phase. The concentration of the IMQ-450 
loaded MEs obtained and further evaluated is reported in Table 1.  451 
 452 
3.4. Imiquimod skin deposition from isostearic acid-saturated solution 453 
At first, a saturated solution of imiquimod in pure ISO (154 ± 0.85 µg/ml) was applied to the skin 454 
tissue for 6 h. The amount accumulated was very high, being 22.27 ± 8.24 µg/cm2. This value is 455 
significantly higher than the one previously obtained from a saturated solution in oleic acid 456 
(IMQ solubility 73 mg/ml) that resulted 1.62 ± 0.40 µg/cm2 (Telo et al., 2016b) This result 457 
confirms the enhancing property of ISO (Aungst, 1989), in particular toward IMQ permeation 458 
(Chollet et al., 1999). The drug remained mainly localized in the epidermis (18.38 ± 9.1 µg/cm2) 459 
and only about 17% was present in the dermis (3.88 ± 2.24 µg/cm2). This data suggests the 460 
presence of an important solvent drag effect, i.e. the penetration of IMQ-saturated isostearic acid 461 
in the SC and a slower/limited diffusion of the drug into the underlying tissues, due to the low 462 
diffusivity of ISO in the hydrophilic derma (Telo et al., 2016a).  463 
Indeed, when stratum corneum sheets were immersed in a solution of imiquimod in isostearic 464 
acid, the increase of SC weight (due to isostearic acid uptake) was 26.0 ± 6.5% and the uptake of 465 
drug into the SC was linearly correlated with the solvent uptake (Figure 6). 466 
  467 
Figure 6. Correlation between the amount of IMQ extracted from the SC and the theoretical amount calculated 468 
considering the solvent uptake (ml/cm
2
) and the IMQ concentration in the solution (µg/ml)   469 
 470 
3.5. Imiquimod skin deposition from microemulsions  471 
Imiquimod was never found in the receptor compartment. 472 
3.5.1. PG-containing microemulsions 473 
4 microemulsions containing PG were selected on the 3/7 oil/Smix dilution line (Figure 1, Table I). 474 
Figure 7 show the skin accumulation obtained from these MEs where IMQ was dissolved.  475 
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 476 
 477 
Figure 7. IMQ skin retention (μg/cm
2
; mean ± sd) in porcine skin (epidermis+dermis) from microemulsions composed 478 
of isostearic acid, TPGS and propylene glycol with increasing water content. All the MEs have a 3/7 oil/Smix ratio, the 479 
exact composition is presented in Table I. The horizontal lines represent the accumulation values obtained from the 480 
commercial cream Imunocare® (Telo et al., 2016a) (mean ± sd). Symbols indicate that IMQ skin levels are statistically 481 
different (p<0.05) from ISO 11 PG (*); ISO 25 PG (§); Imunocare®(@). Panels b report the values separately obtained in 482 
epidermis and dermis 483 
 484 
The result in Figure 7 (IMQ dissolved) highlight that the water % in the system influenced skin 485 
uptake. Indeed, when water content was either 16 or 20%, the deposition was statistically higher 486 
for comparison with 11 and 25%. The reason is not known but could be attributed to an ideal 487 
balance, obtained for a 16-20% water content, between skin hydration (likely increasing with ME 488 
water content) and system flexibility: by increasing water content the order within the lamellar 489 
phase propagated to longer distances, as described in the structural results, possibly reducing drug 490 
mobility. Moreover, the unfavorable hydrophilic layers between drug-loaded lamellae became 491 
thicker and thus more difficult to cross. The horizontal line in the figure refers to the IMQ skin 492 
deposition obtained with the commercial formulation Imunocare® (Telo et al., 2016a), an Aldara® 493 
equivalent, that resulted similar to ISO 16 PG and ISO 20 PG. This result is particularly interesting, 494 
given the 10-fold different drug concentration (approx. 5 mg/g for the cited MEs vs 50 mg/g for 495 
Imunocare®), and indicates a much better transport efficiency for the gel-like ME compared to the 496 
coarse emulsion (composition: isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, 497 
white soft paraffin, polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl 498 
hydroxybenzoate, xanthan gum and purified water).  499 
To evaluate the possibility to increase IMQ skin accumulation, the same ME containing suspended 500 
IMQ (see section 3.3) were evaluated and a 2-4 times higher uptake was found. However, due to 501 
 20 
the high variability, the increase is statistically significant only for ISO 11 PG and ISO 25 PG, and it 502 
is mainly due to an increase in epidermis accumulation (Supplementary Material, Figure S4). This 503 
result could be due to the presence of small IMQ particles trapped in the deep skin farrows that 504 
were not removed by the tape stripping procedure used for skin cleaning.  505 
 506 
3.5.2. Transcutol®-containing microemulsions 507 
When Transcutol®-based systems were evaluated, a higher accumulation was found (Figure 8). A 508 
possible reason is linked to the higher concentration of the vehicle, but it is important to consider 509 
that all of them are saturated, thus characterized by the same thermodynamic activity that is the 510 
driving force for drug diffusion. More probably, the different mesostructure of Transcutol®-based 511 
systems (Figure 4a), more flexible compared to PG-based systems, increased IMQ diffusivity into 512 
the vehicle and favoured IMQ-skin interaction. Indeed, the skin levels obtained with ISO 25 T are 513 
more than 4 times higher with respect to ISO 25 PG (p<0.005). It is also worth underlying that skin 514 
accumulation from ISO 25 T is also statistically higher with respect to Imunocare® (p<0.05). The 515 
better performance of Transcutol®-containing ME with respect to PG-containing ME was also 516 
found in case of cyclosporine skin delivery (Benigni et al., 2018), even if with a different oil phase 517 
and oil/Smix ratio. 518 
The use of oleic acid instead of isostearic acid, slightly reduced the uptake, but the difference was 519 
not statistically significant, in agreement with the comparable mesostructure (Figure 4b).  520 
 521 
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Figure 8. IMQ skin deposition (mean±sd) in epidermis, dermis and in the whole skin, from microemulsions containing 524 
25% water and different oil phase acid (oleic or isostearic acid) and co-surfactant (Transcutol® and PG). The exact 525 
composition of the vehicles is reported in Table I. * Statistically different from ISO25 PG (p<0.005) and from 526 
Imunocare® (p<0.05). The Imunocare ® data are from ref (Telo et al., 2016b) 527 
 528 
 529 
4. Conclusion 530 
In the present paper, viscous microemulsions based on isostearic acid and TPGS were prepared, 531 
characterized and used to deliver imiquimod to the skin. The result obtained show a skin 532 
deposition higher than the one obtained with the commercial formulation, despite the lower drug 533 
loading. The result also permit to infer the important role of the co-surfactant in determining the 534 
microemulsion structure and, as a result, the ME performance.  535 
The formulation ISO 25 T represents a promising vehicle for imiquimod skin delivery; its 536 
composition could take advantage of the biologic activity of isostearic acid, the thickening 537 
properties of TPGS (and potentially its antioxidant power), and the flexibility imparted by 538 
Transcutol® and necessary for an efficient drug deposition into the skin. However, the very 539 
limited size of the gel-like ME region in the pseudo-ternary diagram is a limitation. This 540 
extremely restricted “design space” can make small formulation changes very critical. For this 541 
reason, it will be necessary to optimize this formulation to enlarge the gel-like ME area, for 542 
instance by modifying the surfactant-co-surfactant ratio. 543 
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 Table I. Composition (% w/w)
a 
of the imiquimod-loaded gel-like ME prepared. For all the formulations, the surfactant 
was TPGS and the oil/Smix ratio was 3/7.  
 
CODE
b
 Oil Phase % Co-surfactant % Surfactant 
(TPGS) % 
Water % IMQ conc (mg/g) 
OLE 25 T Oleic acid  20.5 Transcutol® 26.7 26.9 25.9 11.8 
ISO 25 T Isostearic acid  20.5 Transcutol® 26.7 26.9 25.9 13 
ISO 11 PG Isostearic acid  24.1 propylene glycol 32.9 31.7 11.3 21.2
c
 5.3 
ISO 16 PG Isostearic acid  22.6 propylene glycol 31.1 30.0 16.3 20.0
c
 5.0 
ISO 20 PG Isostearic acid  21.7 propylene glycol 29.5 28.5 20.3 19.1
c
 4.8 
ISO 25 PG Isostearic acid  20.4 propylene glycol 27.5 26.5 25.6 17.8
c
 4.5 
a 
the following densities
 
were used for the calculation: isostearic acid:0.89 g/ml; propylene glycol:1.04 g/ml; 
Transcutol®:0.99 g/ml 
b
The code is given by the oil phase used - Oleic(OLE) or Isostearic (ISO) acid, followed by the water percentage and by 
the co-surfactant used (T:Transcutol®, PG:propylene glycol )
 
c
The drug is partially suspended 
 
Table 1
Table II. Imiquimod solubility in the oil phases, co-surfactants and oil/Smix 3/7 mixtures 
Vehicle Solubility (mg/ml) 
ISA 154 ± 0.85 
OLE 73.86 ±14.2* 
Propylene glycol 0.60 ±0.03* 
Transcutol® 1.11 ±0.07* 
OLE/TPGS/Transcutol® (3/4.5/4.5) 13.40 ± 1.28 
ISA/TPGS/Transcutol® (3/4.5/4.5) 16.21 ± 0.13 
ISA/TPGS/propylene glycol (3/4.5/4.5) 23.93 ± 2.83 
* From ref.(Telo et al., 2016) 
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